{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-24-000082","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.734532+00:00","generated_at":"2026-05-30T08:00:27.312880+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M","bullets":["Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).","Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.","Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.","Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.","Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-24-000082","json":"https://secwatch.observer/filing/0001127537-24-000082.json","markdown":"https://secwatch.observer/filing/0001127537-24-000082.md","text":"https://secwatch.observer/filing/0001127537-24-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/0001127537-24-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/lung-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:00:27.312880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}